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Abstract
Retinopathy of prematurity (ROP), a retinal disease characterized by neovascularization
and vasoobliteration, is becoming more prevalent in premature infants as technological advances
succeed in better sustaining the life of infants that are the result of premature birth.
Dimethyloxalylglycine (DMOG) has been proven to lessen the severity of the symptoms of ROP
in mice through the inhibition of prolyl hydroxylase, an enzyme crucial to the degradation of
hypoxia inducible growth factor (HIF). The identification of DMOG as a potential novel
therapeutic treatment for ROP has brought the mechanism by which DMOG functions into
question. To further define this mechanism, wild-type (WT) and liver HIF1α knockout mice
(LHKO) were injected with DMOG and the subsequent expression of target genes in the liver,
kidney, and retina were measured at varying time points. Notable results include the upregulation
of erythropoietin (EPO) and angiopoietin-like 3 (ANGPTL3). Such upregulation proves that
EPO and ANGPTL3 should be considered a key target in future efforts to prevent the formation
of ROP. Furthermore, these results suggest that EPO and ANGPTL3 play a role in protecting the
retina from damaging hyperoxic conditions. It is unclear, however, how EPO and ANGPTL3
directly affect the retina, making it worthy of being studied further. This work serves as a solid
foundation for future examination of the biochemical mechanism of DMOG in the treatment of
ROP.

Introduction
Dr. Theodore L. Terry first reported retinopathy of prematurity in 1942 in the American
Journal of Ophthalmology as retrolental fibroplasia1. Since that time, the scientific community
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has expounded on this disease, coining it as retinopathy of prematurity (ROP) while continuing
to define the expansive pathology behind this disease. With significant advances having been
made in the understanding of preserving premature life, ROP is becoming more prevalent as
more premature infants survive2. To understand the reasoning behind the prevalence of ROP, it is
important to understand the progression of the disease itself.
ROP is defined by two stages characterized by the presence of oxygen and the quality of
the vasculature of the retina. Stage one occurs during the period of time in which a premature
infant is placed into a hyperoxic environment to sustain his or her life. During this time the
excess of oxygen signals still developing tissue, e.g., retina, to cease the production of growth
factors previously present in the hypoxic uterus of the mother3. Without necessary growth
factors, the vasculature of the retina halts in growth, which does not pose any immediate danger.
When the infant reaches a stage in growth in which supplemental oxygen is no longer necessary,
relative hypoxic conditions develop in the retinal tissue due to the lack of blood circulation. It is
important to note that “relative hypoxia” refers to the comparison between the oxygenation in the
mother’s uterus and the premature infant, not to the oxygenation levels in a fully developed
retina. In the presence of relative hypoxia, the stunted growth of vessels poses a problem. Not
enough oxygen is reaching the retina, so the body responds by reactivating pro-angiogenic
growth factors4. These growth factors cause neovascularization to occur in the retina2.
Neovascularization produces weakened vessels incapable of sustaining sufficient blood flow.
The subsequent weakening of vessels ultimately leads to the formation of scaring and in extreme
cases a detached retina and blindness. In short, stage one is characterized by stunted growth in
relative hyperoxic conditions, whereas stage II is characterized by excessive, unorganized
growth in relative hypoxic conditions.
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Experimentation in ROP research has answered many questions about the mechanisms of
this disease, but still has failed to define a definitive cure. Early studies attempted to regulate and
lower oxygen concentrations within the oxygen hoods of premature infants to mimic prenatal
hyperoxic conditions, to great success in preventing ROP3. However, physicians worried that
such oxygen levels contributed to the mortality of premature infants, and such an approach was
abandoned. Since that time, treatment has been focused on post-diagnostic methods, or the
management of the disease after it has developed. Such treatments are invasive and do not
guarantee full functionality of the retina. Those infants surviving with eyesight intact do not
survive without consequences, as corrective lenses will still be required later on in life5. Within
the past few years, novel treatments have arisen, each promising more than the past. One study
suggest that exposure to 670 nm light prevents the vasoobliteration common to this disease6.
The most promising treatments are those that target the inhibition of prolyl hydroxylase, a
molecule that tags hypoxia inducible growth factor (HIF) for degradation in the hyperoxic stage
of the disease. Under normal circumstances, HIF places a crucial role in promoting normal
retinal growth and angiogenesis. In hyperoxic conditions with excess oxygen, prolyl hydroxylase
is active and hydroxylates HIF rendering HIF inactive. When HIF is inactive, blood vessels cease
growth causing a cascade of many negative effects ultimately leading to the loss of vision
(Figure 1). Thus, inhibiting prolyl hydroxylase helps to maintain higher levels of HIF and
prevents the cascade leading to loss of vision. One such inhibitor is dimethyloxalylglycine
(DMOG), which actively inhibits prolyl hydroxylase and “tricks” the body into maintaining
hypoxic processes, allowing for continued growth of retinal blood vessels, similar to those
conditions found in the uterus of the mother. This maintenance of HIF thereby prevents the
degradation of blood vessels (vasoobliteration) and the subsequent occurrence of the rapid
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unorganized growth of vessels (neovascularization), traits that characterize ROP. This approach
is beneficial because it allows for the prevention of the disease and the maintenance of standard
care for premature infants.

Figure 1: HIF Cascade Under Normal Gestation and Premature Conditions7

It has already been established that DMOG is effective in the prevention of
neovascularization and vasoobliteration7. In the mouse model of ROP, commonly referred to as
oxygen-induced retinopathy (OIR), WT mice exposed OIR-inducing conditions exhibited
neovascularization and vasoobliteration (Figure 2B). However, WT mice exposed to OIRinducing conditions and treated with DMOG injections exhibited healthy vascularization (Figure
2C). Figure 2 also shows the importance of HIF in protecting the retina from the destructive
effects of OIR. Scientific literature suggests that DMOG functions primarily through the liver
allowing for many routes of delivery8. Thus HIF1α was removed from nearly 80% of the
hepatocytes in the liver to create the LHKO mouse. As a result, DMOG lost its ability to protect
the retina from OIR-inducing conditions as neovascularization and vasoobliteration occurred
(Figure 2F).
5

Figure 2: Retinal flat mounts of WT and LHKO mice exposed to room air (RA)
[A, D] or OIR-inducing conditions [B, C, E, F].

Scientific literature has already established the importance of HIF in the maintenance and
normal growth of the undeveloped retina. However, it currently not understood which genes or
molecules HIF activates or deactivates in order to have vasoprotective effects of the retina. Thus
the aim of this research is to establish which genes were upregulated in response to the injection
of DMOG in both the WT and LHKO mouse. Scientific literature suggests that erythropoietin
(EPO) plays a crucial role during hypoxic conditions in the body and has the potential to promote
angiogenesis2. This expression during hypoxic conditions contributes to the physiological
response of increasing erythrocytes to better circulate oxygen throughout the body. Considering
that DMOG inhibits prolyl hydroxylase, thereby mimicking hypoxic conditions in the body it is
possible to predict that EPO is crucial to the biochemical mechanism of DMOG.
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Other genes of interest included: Chemokine Ligand 16 (CXCL16), Vascular Endothelial
Growth Factor B (VEGFB), Mannose Receptor C – Type 1 (MRC1), Vascular Endothelial
Growth Factor A (VEGFA), Angiopoietin Like 3 (ANGPTL 3), Insulin-like Growth Factor-1
(IGF-1). The previously mentioned genes were identified as genes of interest based on a
previously conducted Genechip microarray. A Genechip microarray measured the differentially
expressed genes within the liver 6 hours after the administration of DMOG7. CXCL16 is thought
to be chemokine that influences angiogenesis. VEGFA promotes vascular growth through
increasing endothelial cell permeability. VEGFB works by maintaining the newly formed blood
vessels created by VEGFA. MRC1 was indicated as upregulated by the gene chip for unknown
reasons. Scientific literature suggests that MRC1 is crucial in immune responses. If MRC1 is
actually upregulated in response to DMOG injections, it may suggest a possible immunological
mechanism. IGF-1 plays a role in childhood growth. Finally ANGPTL3 contains a c-terminal
that has been known to function in angiogenesis.
Using reverse transcriptase polymerase chain reactions (RT-PCR), it is possible to
determine which of the previously mentioned genes are upregulated in the WT mouse and which
genes are unaffected in the LHKO mouse. This information will help to define a mechanism by
which DMOG functions to protect the retina from developing ROP.

Methods
Mice Preparation for Retinal Flatmounts. To induce OIR in mice, a protocol previously
established by Smith, et. al was followed8. The OIR mouse model mimics the formation of ROP
in humans. Unlike the fully developed retina of a full-term human baby, the mouse retina in
healthy pup is underdeveloped. This allows for the undeveloped retina to be studied without
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having to induce early labor in the mother. Additionally, the most notable difference in the
mouse model is that vasoobliteration occurs in the central portion of the retina. In ROP,
vasocessation occurs in the peripheral retina. Otherwise, the OIR mouse model is suitable for
studying ROP, especially because of its reproducibility and affordability. To develop OIR in
mice, C57BL/6J mice pups were exposed to hyperoxic environments (75% oxygen) over the
span of time ranging from 7 to 12 days after birth in a Plexiglas incubator with an adjustable
oxygen sensor and feedback system (Pro-Ox)4. Mouse pups were injected with DMOG or PBS
on postnatal day 6 (P6), P8, and P10. On P12 the pups were placed in room air until P17, when
the retinas were extracted for analysis. The retinal flat mounts and lectin stains were completed
in accordance with a protocol previously established by Connor et al9.

Mice Preparation for Gene Expression Measurement by RT-PCR.
Mice included in the study were those of C57BL/6J wild-type (WT) genotype and mice with the
Liver HIF1α gene removed from nearly 80% of the hepatocytes (LHKO). LHKO mice were bred
at the Jackson Laboratory. P8 mice were injected intraperitoneally with 200 micrograms/gram
mouse weight of DMOG.

Organ Processing and RT-PCR. After the designated time of 3, 6, or 24 hours after injections,
the kidney, liver, and retina were dissected and preserved in Qiagen RNAlater reagent overnight.
Organs collected at the 0 hour time point served as a control group and did not receive any
injections. Afterward, organs were stored in at -80°C until the organs could be further processed.
The collected organs were processed using Qiagen QiaShredder and Qiagen RNeasy MiniKit to
isolate RNA from the organs. The RNA was further converted into cDNA utilizing Qiagen
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QuantiTect Reverse Transcription Kit. The expression of particular genes was measured using
Qiagen QuantiTect SYBR Green PCR kit and Qiagen QuantiTect Primer Assays for respective
genes of interest. The genes of interest analyzed included: CXCL16, VEGFB, MRC1, EPO,
VEGFA, ANGPTL 3, IGF-1, and Hypoxanthine-guanine phosphoribosyltransferase (HPRT) as
an endogenous control. Results were measured and quantified using RQ Manger Software.
Statistical significance was measured in excel using the t-test, non-paired, equal variance.

Results
Conducting RT-PCR using EPO as the target gene in the liver yielded results show a
marked increases in expression levels at all time points in the WT mouse. Similar but muted
results were demonstrated in the liver of the KO mouse (Figure 3A).
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Figure 3: The levels of EPO gene expression in response to DMOG injections in both WT and
KO mice after 0, 3, 6, and 24-hour intervals. (A) The measured gene expression in the liver of the
WT and KO mice (B) The measured gene expression in the kidney of the WT and KO mice (C)
The measured gene expression in the retina of the WT and KO mice.

The gene expression of EPO in the liver of the DMOG-injected WT mice yielded a nearly 200fold increase at 3 hours. This level of EPO gradually decreased with each successive time point,
but still maintained elevated levels compared to those injected for 0 hours. KO mice expressed
lower levels of EPO expression than the WT, but still shared a similar gene expression pattern
with a peak expression at 3 hours and a successive decrease (Figure 3A). This gene expression in
the liver of KO mice compared to WT mice was statistically different at 3, 6, and 24 hours (ttest, non-paired, equal variance at 3-hours: p-value = 0.04, 6-hours: p-value = 0.003, 24-hours: pvalue = 0.02. The kidney expression of EPO was less in comparison with the liver (Figure 3B).
Additionally, KO mice exhibited similar levels of EPO expression at each time point compared
to the WT mice. Maximum expression occurred 5-fold at 3 hours in the WT and KO mice. The
retina had the lowest levels of induced expression of EPO (Figure 3C). No difference is
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detectable between the WT and KO mice, with peak expression occurring by 1.75-fold at 3 hours
post-injection.
When ANGPTL3 was used as the target gene for RT-PCR results indicated that the gene
expression in the liver gradually increased in both the WT and KO mice as time progressed
(Figure 4a). The levels of expression at 3-hours were not statistically different from the levels of
expression at 0 hours (p-value = 0.08). However, both the 6 (p-value = 0.03) and 24-hour time
point (p-value = 0.00004) were statistically significant. The p-value was based on the t-test, nonpaired, equal variance. This suggests that the gene expression of ANGPTL3 in response to
DMOG is not immediate like the expression of EPO. Furthermore, a 5-fold induction occurred at
24 hours in WT and a 4-fold induction occurred in KO mice. The expression of ANGPTL3 in
KO mice is muted in comparison to WT. Experimentation concerning the kidney and retina had
not been completed by the time of this publication.
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Figure 4: The levels of ANGPTL3 gene expression in response to DMOG injections in the liver
of both WT and KO mice after 0, 3, 6, and 24-hour intervals.

The measured gene expression of CXCL16 in response to DMOG yielded results that
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demonstrated that the expression levels appeared to be unaffected by DMOG administration
(Figure 5A). Given that the levels of gene expression did not vary after injection with DMOG,
KO mice were not examined for CXCL16 gene expression.
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Figure 5: The levels of CXCL16 gene expression in response to DMOG injections in the liver of
only WT mice after 0, 3, 6, and 24-hour intervals.

The measured gene expression of VEGFB in response to DMOG yielded results that
demonstrated that the expression levels appeared to be unaffected by DMOG administration
(Figure 6A). Given that the levels of gene expression did not vary after injection with DMOG,
KO mice were not examined for VEGFB gene expression. A similar conclusion was reached for
both IGF-1 and MRC1 (Figures 7A and 8A, respectively).
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Figure 6: The levels of VEGFB gene expression in response to DMOG injections in the liver of
only WT mice after 0, 3, 6, and 24-hour intervals.
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Figure 7: The levels of IGF-1 gene expression in response to DMOG injections in the liver of
only WT mice after 0, 3, 6, and 24-hour intervals.
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Figure 8: The levels of MRC1 gene expression in response to DMOG injections in the liver of
only WT mice after 0, 3, 6, and 24-hour intervals.

The gene expression of VEGFA in response to DMOG in the liver markedly increased between
the 0 and 3 hour time point in WT mice, but gradually decreased as time progressed (Figure 9A).
A 3-fold maximal induction occurred at 3 hours. While the expression in both WT and KO mice
was evaluated, the gene expression between KO and WT mice at each time point did not differ.
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Figure 9: The levels of VEFGA gene expression in response to DMOG injections in the liver of
WT and KO mice after 0, 3, 6, and 24-hour intervals.

Discussion
The results of RT-PCR indicated an upregulation of EPO, ANGPTL3, and VEGFA in
response to DMOG injections. However, contrary to what was expected, MRC1, IGF-1, VEGFB,
and CXCL16 did not have altered expression levels after the injection of DMOG. Even still, such
information plays a crucial role in the establishment of the biochemical mechanism of DMOG.
Like humans, EPO expression normally occurs in the kidney of mice. However,
experimental results indicated that the levels of expression from the liver were more elevated
than the kidney. Using imaging techniques in previous studies, however, it is possible to observe
that DMOG functions primarily through the liver, which could serve as an explanation as to why
induction was so exponential in the liver. As previously mentioned in the introduction, it is not
surprising that EPO expression was markedly increased after the injection of DMOG. This is
because EPO is expressed in the body as a response to hypoxic conditions1. This expression
during hypoxic conditions contributes to the physiological response of increasing erythrocytes to
better circulate oxygen throughout the body. Considering that DMOG inhibits prolyl
hydroxylase, thereby mimicking hypoxic conditions in the body, it serves as no surprise that
EPO is released as a response.
EPO gene expression was also upregulated in the KO mice. This raises the question: how is
it that EPO expression is still upregulated in the liver even though KO mice retinas cannot be
protected by DMOG from the formation of ROP (refer to Figure 1)? While EPO expression is
upregulated in the KO mouse, it is not upregulated to the same extent as in WT mice. This
difference between the WT and KO mice suggest these varying levels of expression are enough
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to make a difference between a healthy retina and one that is plagued by ROP. It is also
important to remember that muted levels of gene expression from the KO mice are expected.
This is because HIF1α was only removed from 80% of the hepatocytes of the liver. The
hepatocytes only account for some of the cells contained in the liver. This means that other liver
cells are still capable of producing genes that would function to preserve the retina in WT mice,
however the levels in the KO mice are muted enough to be deemed ineffective.
This research establishes the role that EPO contributes after injections of DMOG; however,
it is also known that EPO cannot function alone to save the retina from ROP. In previous
experiments, mice exposed to OIR and given injections of only EPO still developed ROP. Thus,
it is believed that while DMOG induces heightened expression of EPO, other molecules are
crucial in the preservation of the retina. This research helped to establish that IGF-1, CXCL16,
MRC1, VEGFA, and VEGFB do not work alongside DMOG to achieve a vasoprotective effect.
However, the effect of ANGPTL3 is worth being investigated further.
ANGPTL3 is known for being expressed mainly in the liver2. Thus, the expression of this
gene from the liver is expected. Additionally, scientific literature suggests that ANGPTL3
functions to promote angiogenesis. Given the increase of ANGPTL3 in response to DMOG it
may be possible that ANGPTL3 works alongside EPO, in promoting angiogenesis thereby
preventing the progression of ROP in WT mice. Furthermore, the muted response from KO mice
may suggest that lower levels of ANGPTL3 compared to the WT may account for the lost ability
of the KO mice to preserve the retina. To further establish the role that ANGPTL3 may play in
biochemical mechanism of DMOG, it is important to complete the RT-PCR results for both the
kidney and retina.
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While these results suggest that EPO and ANGPTL3 play a role in protecting the retina
from damaging hyperoxic conditions, it is still unclear, however, how EPO and ANGPTL3
directly affect the retina, making it worthy of being studied further. This work serves as a solid
foundation for future examination of the biochemical mechanism of DMOG in the treatment of
ROP.
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